Drug Profile


Alternative Names: Solosec™; SYM 1219

Latest Information Update: 22 Aug 2016

Price : $50

At a glance

  • Originator Symbiomix Therapeutics
  • Class Antibacterials; Antiprotozoals; Nitroimidazoles; Small molecules
  • Mechanism of Action DNA synthesis inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    Bacterial vaginosis
  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Bacterial vaginosis

Most Recent Events

  • 17 Aug 2016 Efficacy data from a phase III trial in Bacterial vaginosis released by Symbiomix
  • 21 Sep 2015 Pharmacokinetics data from a phase I trial in Healthy-volunteers released by Symbiomix Therapeutics
  • 27 Aug 2015 Secnidazole receives Fast Track designation for Bacterial vaginosis [PO] in USA
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top